Patient Square Capital

Patient Square Capital focuses on a healthcare investment firm that partners with best-in-class management teams whose products, services, and technologies improve health. They use extensive industry expertise, a large network of relationships, and a partnership approach to help organizations develop and succeed.

Alex Albert

Founding Partner

Talia Anderson

Principal Director

Vasundhara Bhargava

Principal

Hannah Carlino

Vice President

Daniel Fishbaum

Investor

Daniel Fishbaum

Associate

Laura Furmanski

Partner and Head of Patient Square Insights

Trit Garg

Vice President

David Katz

Partner

Ken Michalzuk

Managing Director

Jim Momtazee

Managing Partner

James Momtazee

Managing Partner

Karr Narula

Founding Partner

Will Sauser

Associate

Nate Seaman

Executive Director

Udaivir Singh

Associate

Richard Stec

Executive Director

Neel Varshney

Founding Partner

Matthew Whelan

Partner and CFO

Eric Zhang

Principal

8 past transactions

Elevage Medical Technologies

Private Equity Round in 2023
Elevage Medical Technologies is dedicated to supporting medical device companies that can meaningfully improve health outcomes and quality of life for patients.

Eargo

Post in 2022
Eargo specializes in the design and development of hearing aids. The company also offers online hearing screenings and virtual support, so customers don’t need to have an in-person visit. It offers rechargeable hearing aids that can be controlled with a smartphone. Its innovative product and go-to-market approach address the challenges of traditional hearing aid adoption, including social stigma, accessibility, and cost.

Alladapt Immunotherapeutics

Venture Round in 2022
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

Kriya Therapeutics

Series C in 2022
Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. They have built a fully integrated engine that consolidates the critical infrastructure and technology needed to engineer, manufacture, characterize, and develop new gene therapies

Enavate Sciences

Private Equity Round in 2022
Enavate Sciences is committed to investing in and supporting the strategic growth of innovative therapeutic and enabling technology companies.

Roivant Sciences

Post in 2021
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.

Kriya Therapeutics

Series B in 2021
Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy. They have built a fully integrated engine that consolidates the critical infrastructure and technology needed to engineer, manufacture, characterize, and develop new gene therapies

Apollo Therapeutics

Venture Round in 2021
Apollo Therapeutics is a collaborative venture between three UK universities (Imperial College London, University College London, and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best British academic research, accelerating them towards the clinic. Apollo’s unique model provides quick, independent access to the resources to grow innovations and champion the best British academic research to industry. Apollo’s experienced team of industry scientists has a proven track record of therapeutic delivery and works in partnership with academics and industry partners, crafting each bespoke project to optimize the chances of long-term success. Apollo Therapeutics aims to create future therapies by partnering with the UK’s globally leading academic science base and UK-based Pharma industry to have a real impact on patient treatments and outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.